Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
Based on these pre-clinical data, which were generated by our group, the investigators
propose to test in a phase I/II clinical trial the following hypothesis: demethylation
induced by decitabine results in re-sensitization to platinum in recurrent ovarian cancer.
To test this hypothesis, the investigators will treat patients with recurrent ovarian cancer
platinum resistant (recurrence within 6 months from platinum therapy) or platinum-refractory
(no response to platinum) with a combination consisting of decitabine and carboplatin.
This will be an institutional open label phase I/II trial to determine the safety and the
biologic activity of the Decitabine/Carboplatin combination.
The investigators will determine whether Carboplatin can be safely combined with Decitabine,
the optimal dose schedule and the investigators will define whether at this dosage, the
regimen is biologically active (i.e. induces demethylation of target genes).
In the second part of the trial, the investigators will determine the clinical activity of
the combination in a population of patients with platinum-resistant ovarian cancer.